Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab in Relapsed or Refractory INI1-negative Cancers
NCT04416568Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Aug 2020
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and ipilimumab in malignant rhabdoid tumor (MRT), Rhabdoid Tumor of the Kidney (RTK), epithelioid sarcoma (ES) and 4 more (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Objective Response Rate at 12 months. Started Aug 2020; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
malignant rhabdoid tumor (MRT)Rhabdoid Tumor of the Kidney (RTK)epithelioid sarcoma (ES)chordomaAtypical teratoid rhabdoid tumor (ATRT)
Beyond the preview
Go deeper on NCT04416568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04416568.